Oraqix (Lidocaine, Prilocaine)

Lidocaine, the active ingredient in Oraqix, is a local anesthetic presented as a topical formulation for intra‑oral use. It provides surface anesthesia for dental procedures, helping to reduce discomfort during minor oral surgeries and examinations. GNH USA supplies Oraqix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oraqix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oraqix is a topical anesthetic used in dentistry to provide localized numbness of oral mucosal tissues.

- Dental procedures: Reduces pain and discomfort during minor surgical interventions such as extractions and biopsies. - Periodontal therapy: Facilitates scaling, root planing and other non‑surgical periodontal treatments. - Diagnostic examinations: Allows comfortable probing and assessment of oral lesions. - Pediatric dentistry: Provides a child‑friendly anesthetic option for simple restorative work. - Oral mucosal lesions: Helps alleviate pain from traumatic or ulcerative lesions. - Pre‑operative preparation: Used to anesthetize the site before more invasive oral surgery.

Oraqix may cause local or systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Transient burning or stinging sensation at the application site. - Mild erythema or redness of the oral mucosa. - Temporary alteration of taste perception. - Minor swelling or edema of the gingival tissue. - Light‑headed dizziness if absorbed in larger amounts.

Serious or Rare Side Effects: - Allergic reactions such as urticaria, angio‑edema or anaphylaxis. - Methemoglobinemia, particularly with excessive exposure to prilocaine. - Persistent numbness beyond the expected duration. - Cardiovascular disturbances including hypotension or arrhythmia. - Central nervous system toxicity presenting as seizures or altered consciousness.

When using Oraqix, clinicians should assess patient history and follow recommended handling practices.

- Allergy assessment: Verify no known hypersensitivity to lidocaine, prilocaine or amide‑type anesthetics. - Dose limitation: Avoid exceeding the maximum recommended surface area to reduce systemic absorption. - Medical conditions: Use caution in patients with cardiac, hepatic or renal impairment. - Drug interactions: Review concurrent medications that may potentiate local anesthetic toxicity. - Pediatric use: Adjust application area and monitor closely in children. - Store at ambient temperature: Keep below 25°C, protect from moisture and direct sunlight.

Oraqix can interact with systemic medications that affect cardiac conduction or increase the risk of local‑anesthetic toxicity.

Major Interactions (Avoid): - Class I anti‑arrhythmic agents (e.g., quinidine, procainamide) – may exacerbate cardiac conduction delays. - Monoamine oxidase inhibitors (MAOIs) – increase risk of systemic toxicity when large amounts are absorbed.

Moderate Interactions (Monitor Closely): - Beta‑blockers and calcium‑channel blockers – may potentiate hypotensive effects. - CNS depressants (e.g., benzodiazepines, opioids) – enhance central nervous system depression if systemic absorption occurs. - Certain antibiotics such as erythromycin – can alter plasma protein binding of local anesthetics. - Anticoagulants (e.g., warfarin) – may increase bleeding risk at the application site. - Herbal supplements containing ephedra – may raise blood pressure and heart rate, influencing anesthetic safety.